EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma

Yue Wan, Xiangxiang Liu, Xuejing Yan, Shen Wu, Yufei Teng, Luyi Han, Jingxue Zhang, Ningli Wang

Investigative Ophthalmology & Visual Science · 2026

DOI: 10.1167/iovs.67.1.48 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Yue Wan and 7 co-authors. Institution: Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Major MEDLINE topics: Cytoskeletal Proteins, Eye Proteins, Glycoproteins, Dependovirus. Cited 1 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Purpose

To evaluate the therapeutic efficacy of an adeno-associated virus serotype DJ (AAV-DJ) vector delivering MYOC-targeting short-hairpin RNA (shMYOC) in a MYOCP370L transgenic glaucoma mouse model (Tg-MYOCP370L) for the treatment of open-angle glaucoma (OAG) associated with MYOC mutations.

Methods

An AAV-DJ vector, selected for its high transduction efficiency and tropism for trabecular meshwork (TM), was used to deliver shMYOC via a transpupillary intravitreal approach in Tg-MYOCP370L mice. Post-treatment evaluations included myocilin accumulation, ER stress marker expression, intraocular pressure (IOP), aqueous humor outflow facility, retinal ganglion cell (RGC) survival, and visual function.

Results

AAV-DJ-shMYOC markedly reduced myocilin accumulation and ER stress markers in TM cells in vivo, effectively preventing age-dependent IOP elevation, preserving aqueous humor outflow facility, and maintaining RGC survival and visual function in young Tg-MYOCP370L mice. In aged Tg-MYOCP370L mice, AAV-DJ-mediated MYOC silencing similarly lowered IOP and improved outflow facility.

Conclusions

AAV-DJ-mediated MYOC silencing effectively alleviated glaucomatous pathology in Tg-MYOCP370L mice, highlighting its potential as a gene therapy strategy for myocilin-associated glaucoma.

Subjects

MeSH terms (MEDLINE)

Cytoskeletal ProteinsEye ProteinsGlycoproteinsDependovirusGenetic TherapyGlaucoma, Open-AngleGene SilencingAnimalsMyocilinMiceIntraocular PressureDisease Models, AnimalMice, TransgenicTrabecular MeshworkAqueous HumorGenetic VectorsRetinal Ganglion CellsRNA, Small InterferingGene Therapy Agents

Substances

MyocilinCytoskeletal ProteinsEye ProteinsGlycoproteinsRNA, Small Interfering

Authors and institutions

  • Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Beijing Key Laboratory of Intelligent Diagnosis Technology and Equipment for Optic Nerve-Related Eye Diseases, Capital Medical University, Beijing, China.
  • Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China.

Cite

APA

Wan, Y., Liu, X., Yan, X., Wu, S., Teng, Y., Han, L., Zhang, J., & Wang, N. (2026). AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.1.48

Vancouver

Wan Y, Liu X, Yan X, Wu S, Teng Y, Han L, et al. AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.1.48

BibTeX
@article{Wan2026,
  author = {Wan, Yue and Liu, Xiangxiang and Yan, Xuejing and Wu, Shen and Teng, Yufei and Han, Luyi and Zhang, Jingxue and Wang, Ningli},
  title = {AAV-DJ–Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2026},
  doi = {10.1167/iovs.67.1.48}
}
Start for free →